Update on Clinical Trials for Nonalcoholic Steatohepatitis.
Tremendous effort has been put forth over the past 2 decades in understanding the pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Although multiple potential targets for drug development exist, there have been no approved therapies for NAFLD/NASH. Lipot...
| Publicado en: | Gastroenterology & Hepatology Vol. 19; no. 7; pp. 371 - 382 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Gastro-Hep Communications, Inc
Jul2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=165629359&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 165629359 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15547914 6N5B jtl: Gastroenterology & Hepatology issn: 15547914 maglogo: N pubinfo: dt: Jul2023 vid: 19 iid: 7 pid: 72163 pub: Gastro-Hep Communications, Inc place: New York, New York artinfo: ui: 165629359 165629359 165629359 165629359 ppf: 371 ppct: 11 formats: fmt: @attributes: type: P tig: atl: Update on Clinical Trials for Nonalcoholic Steatohepatitis. aug: au: Nathani, Rohit R. Bansal, Meena B. affil: Department of Medicine, Mount Sinai West and Morningside Hospital, New York, New York sug: subj: Clinical Trials Nonalcoholic Fatty Liver Disease Physiopathology Nonalcoholic Fatty Liver Disease Drug Therapy Drugs, Investigational Therapeutic Use Drug Therapy, Combination Drug Efficacy Drug Synergism Adverse Drug Event Prevention and Control Bile Acids and Salts Therapeutic Use Heterocyclic Compounds Therapeutic Use Drugs, Investigational Pharmacodynamics ab: Tremendous effort has been put forth over the past 2 decades in understanding the pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Although multiple potential targets for drug development exist, there have been no approved therapies for NAFLD/NASH. Lipotoxicity, owing to increased delivery of fatty acids to the liver, and hepatic de novo lipogenesis are key drivers of disease pathogenesis. Moreover, genetics, environmental factors, and comorbid conditions converge to determine disease progression in individual patients. Given the complexity and heterogeneity of disease pathogenesis, numerous therapeutic targets have emerged and have been tested in clinical trials. Early trial failures have provided key lessons and foundational insights to move the field forward. Current ongoing phase 3 trials and emerging phase 2 trials are reasons for optimism, and 2 drugs, obeticholic acid and resmetirom, are being evaluated for accelerated approval by the US Food and Drug Administration this year. This article highlights key features of NASH pathophysiology and drug targets, the lessons learned from completed trials, and the current landscape of phase 2 and 3 clinical trials in NASH. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|